BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rosner MH, Jhaveri KD, McMahon BA, Perazella MA. Onconephrology: The intersections between the kidney and cancer. CA Cancer J Clin 2021;71:47-77. [PMID: 32853404 DOI: 10.3322/caac.21636] [Cited by in Crossref: 8] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Rosner MH, Darmon M, Ostermann M. Onco-nephrology: what the intensivist needs to know. Intensive Care Med 2022. [PMID: 35943571 DOI: 10.1007/s00134-022-06840-9] [Reference Citation Analysis]
2 Jiang J, Chan L, Nadkarni GN. The promise of artificial intelligence for kidney pathophysiology. Curr Opin Nephrol Hypertens 2022;31:380-6. [PMID: 35703218 DOI: 10.1097/MNH.0000000000000808] [Reference Citation Analysis]
3 García-Carro C, Draibe J, Soler MJ. Onconephrology: Update in Anticancer Drug-Related Nephrotoxicity. Nephron 2022;:1-13. [PMID: 35717937 DOI: 10.1159/000525029] [Reference Citation Analysis]
4 Shang X, Zhang X, Huang Y, Zhu Z, Zhang X, Liu S, Liu J, Tang S, Wang W, Yu H, Ge Z, He M. Temporal trajectories of important diseases in the life course and premature mortality in the UK Biobank. BMC Med 2022;20:185. [PMID: 35619136 DOI: 10.1186/s12916-022-02384-3] [Reference Citation Analysis]
5 Bolufer M, García-carro C, Blasco M, Quintana LF, Shabaka A, Rabasco C, Draibe J, Merino A, Melero MR, Alonso F, Buxeda A, Batalha P, Visús MT, Soler MJ. Kidney Biopsy in Patients with Cancer along the Last Decade: A Multicenter Study. JCM 2022;11:2915. [DOI: 10.3390/jcm11102915] [Reference Citation Analysis]
6 Singh R, Nasci VL, Guthrie G, Ertuglu LA, Butt MK, Kirabo A, Gohar EY. Emerging Roles for G Protein-Coupled Estrogen Receptor 1 in Cardio-Renal Health: Implications for Aging. Biomolecules 2022;12:412. [DOI: 10.3390/biom12030412] [Reference Citation Analysis]
7 Perazella MA, Herlitz LC. The Crystalline Nephropathies. Kidney Int Rep 2021;6:2942-57. [PMID: 34901567 DOI: 10.1016/j.ekir.2021.09.003] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
8 Lederer ED, Brier ME. Cancer Therapy in a Data Vacuum. Dis Colon Rectum 2021;64:1441-3. [PMID: 34561345 DOI: 10.1097/DCR.0000000000002254] [Reference Citation Analysis]
9 Nervo A, Retta F, Ragni A, Piovesan A, Mella A, Biancone L, Manganaro M, Gallo M, Arvat E. Nephrotoxicity in advanced thyroid cancer treated with tyrosine kinase inhibitors: An update. Crit Rev Oncol Hematol 2021;168:103533. [PMID: 34801702 DOI: 10.1016/j.critrevonc.2021.103533] [Reference Citation Analysis]
10 Bai Y, Kim JY, Bisunke B, Jayne LA, Silvaroli JA, Balzer MS, Gandhi M, Huang KM, Sander V, Prosek J, Cianciolo RE, Baker SD, Sparreboom A, Jhaveri KD, Susztak K, Bajwa A, Pabla NS. Kidney toxicity of the BRAF-kinase inhibitor vemurafenib is driven by off-target ferrochelatase inhibition. Kidney Int 2021:S0085-2538(21)00855-3. [PMID: 34534550 DOI: 10.1016/j.kint.2021.08.022] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
11 Vlasschaert C, Moran SM, Rauh MJ. The Myeloid-Kidney Interface in Health and Disease. Clin J Am Soc Nephrol 2021:CJN. [PMID: 34507968 DOI: 10.2215/CJN.04120321] [Reference Citation Analysis]
12 Mitsuboshi S, Niimura T, Yoshino M, Sakamoto Y, Zamami Y, Ishizawa K. Fluoropyridmidine use and hypertriglyceridemia among Japanese patients: analysis of adverse event database. Int J Clin Pharm 2021. [PMID: 34482500 DOI: 10.1007/s11096-021-01324-0] [Reference Citation Analysis]
13 Rosner MH, DeMauro Renaghan A. Disorders of Divalent Ions (Magnesium, Calcium, and Phosphorous) in Patients With Cancer. Adv Chronic Kidney Dis 2021;28:447-459.e1. [PMID: 35190111 DOI: 10.1053/j.ackd.2021.09.005] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Cosmai L, Porta C, Foramitti M, Rizzo M, Gallieni M. The basics of onco-nephrology in the renal clinic. J Nephrol 2020;33:1143-9. [PMID: 33242211 DOI: 10.1007/s40620-020-00922-x] [Reference Citation Analysis]
15 Cervantes CE, Kant S, Atta MG. The Link Between Conventional and Novel Anti-Cancer Therapeutics with Thrombotic Microangiopathy. Drug Metab Lett 2021;14:97-105. [PMID: 34279209 DOI: 10.2174/1872312814666210716141633] [Reference Citation Analysis]
16 Belliere J, Mazieres J, Meyer N, Chebane L, Despas F. Renal Complications Related to Checkpoint Inhibitors: Diagnostic and Therapeutic Strategies. Diagnostics (Basel) 2021;11:1187. [PMID: 34208848 DOI: 10.3390/diagnostics11071187] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
17 Ozawa M, Ohtani H, Komatsuda A, Wakui H, Takahashi N. VEGF-VEGFR2 inhibitor-associated hyaline occlusive glomerular microangiopathy: a Japanese single-center experience. Clin Exp Nephrol 2021. [PMID: 34115234 DOI: 10.1007/s10157-021-02090-z] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
18 Morel A, Meuleman MS, Moktefi A, Audard V. Renal Diseases Associated with Hematologic Malignancies and Thymoma in the Absence of Renal Monoclonal Immunoglobulin Deposits. Diagnostics (Basel) 2021;11:710. [PMID: 33921123 DOI: 10.3390/diagnostics11040710] [Reference Citation Analysis]